Neprilysin
(Homo sapiens (Human)) | BDBM300335
(US9593110, 37-1)Show SMILES C[C@H](N)C(=O)N[C@H](C[C@@H](Cc1ccc(cc1)-c1cc(Cl)ccc1F)NC(=O)c1cnn[nH]1)C(O)=O Show InChI InChI=1S/C23H24ClFN6O4/c1-12(26)21(32)29-19(23(34)35)10-16(28-22(33)20-11-27-31-30-20)8-13-2-4-14(5-3-13)17-9-15(24)6-7-18(17)25/h2-7,9,11-12,16,19H,8,10,26H2,1H3,(H,28,33)(H,29,32)(H,34,35)(H,27,30,31)/t12-,16+,19+/m0/s1 | PDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| KEGG PC cid PC sid UniChem
| US Patent
| <1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Theravence Biopharma R&D IP, LLC
US Patent
| Assay Description Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp... |
US Patent US9593110 (2017)
BindingDB Entry DOI: 10.7270/Q2MC9224 |